Olanzapine
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting
Conditions
Fasting
Trial Timeline
Aug 1, 2011 → Sep 1, 2011
NCT ID
NCT01503398About Olanzapine
Olanzapine is a phase 1 stage product being developed by Dr. Reddy's Laboratories for Fasting. The current trial status is completed. This product is registered under clinical trial identifier NCT01503398. Target conditions include Fasting.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01503398 | Phase 1 | Completed |
| NCT01503424 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting